JJJingwei Jiang

Jingwei Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingwei Jiang has a total of 143 co-authors. Here are the top co-authors by number of shared publications:

  • Hongyi Luo

    New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, China

    4 shared publications
  • Li Sun

    New Drug Screening and Pharmacodynamics Evaluation Center, National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing, China.

    4 shared publications
  • Huiqin He

    Jiangsu Key Lab of Drug Screening, China Pharmaceutical University, Nanjing, China

    3 shared publications
  • Benquan Liu

    Jiangsu Key Lab of Drug Screening, China Pharmaceutical University, Nanjing, China

    2 shared publications
  • Danyu Du

    Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009 China

    2 shared publications
  • Han Tian

    Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China

    2 shared publications

Latest Publications

  • CRISPR screens identify ACSL4 as a key regulator in macrophage activation and metabolic inflammation

    by Yanting Lin, Dongquan Jing, Yiming Liu, Rui Gao, Qixiang Zhao, Xingyu Jiang, Huijuan Da, Yiming Ren, Qiuhua Cao, Jingwei Jiang, et al.

    Background and Purpose: Pro‐inflammatory macrophages drive obesity‐associated metabolic inflammation. Identifying key regulators of their activation is crucial for new therapies. This study aimed to identify novel regulators of pro‐inflammatory adipose tissue macrophage (ATM) activation and assess their therapeutic potential. Experimental Approach: We combined genome‐wide CRISPR‐Cas9 screening with scRNA‐seq data from human adipose tissue and identified long‐chain acyl‐CoA synthetase 4 (ACSL4) as critical for pro‐inflammatory ATM activation. Validation used myeloid‐specific Acsl4 knockout mice ( Acsl4 fl/fl Lyz2 Cre ) and shRNA‐mediated knockdown in macrophage cell lines (RAW264.7, THP‐1, and iBMDM). Mechanisms were explored via mutagenesis, immunostaining, co‐immunoprecipitation (co‐IP), bimolecular fluorescence complementation (BiFC), and transcriptional activity assays. A high‐throughput screen of 8,685 DrugBank compounds was performed to identify candidates targeting ACSL4. Key Results: ACSL4 deficiency markedly reduced pro‐inflammatory factor expression ( Tnfα , Il1β , and Il6 ). Myeloid ACSL4 deletion protected against high‐fat diet (HFD)‐induced obesity, correlated with reduced pro‐inflammatory ATMs and enhanced adipocyte lipolysis and thermogenesis, without affecting food intake, water intake, or locomotor activity in mice. However, glucose tolerance and insulin sensitivity were not significantly affected. Mechanistically, ACSL4 contributed to inflammation independent of its enzymatic/ferroptotic functions (Thr328 mutation, troglitazone insensitivity). Instead, ACSL4 translocated to the nucleus in a karyopherin β1 (KPNB1)‐dependent manner. DrugBank screening identified abemaciclib as a potential inhibitor of the ACSL4‐KPNB1 interaction. Notably, abemaciclib treatment reduced macrophage inflammation and attenuated HFD‐induced obesity in mice. Conclusions and Implications: ACSL4 promotes pro‐inflammatory macrophage activation through its KPNB1‐dependent nuclear translocation and cooperation with IRF5. Targeting the ACSL4‐KPNB1 interaction may represent a potential therapeutic strategy for metabolic inflammation.

  • Open Access

    Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma

    by Weiwei Hu, Jiaping Ni, Shufang Zheng, Xiaohui Wei, Dongqing Zhai, Jinglin Qi, Xinqi Ye, Mingyin Lu, Hanrui Bian, Jintong Li, et al.


  • Open Access

    Integrated screening identifies GPR31 as a key driver and druggable target for metabolic dysfunction–associated steatohepatitis

    by Xiao-Jing Zhang, Jiajun Fu, Xu Cheng, Hong Shen, Hailong Yang, Kun Wang, Wei Li, Han Tian, Tian Tian, Junjie Zhou, et al.

    Metabolic dysfunction–associated steatohepatitis (MASH) is a globally prevalent but intractable disease lacking effective pharmacotherapies. Here, we performed an integrated multilayered screening for pathogenic genes and druggable targets for MASH. We identified the subclass of metabolite-sensing G protein–coupled receptors, specifically GPR31, a critical contributor to MASH occurrence, which, to our knowledge, was previously uncharacterized. Mechanistically, Gαi3 is the essential downstream effector for the pro-MASH efficiency of GPR31 via glycosylation-dependent interaction with GPR31 and extra activation of PKCδ-MAPK signaling. Hepatocyte-specific GPR31 deficiency robustly blocked hepatic lipotoxicity and fibrosis in a mouse model of diet-induced MASH, whereas expression of the GPR31 transgene aggravated MASH development. Of translational importance, we developed a small-molecule inhibitor, named G4451, that specifically inhibits the GPR31-Gαi3 interaction by targeting the GPR31 conformational transition. Encouragingly, oral administration of G4451 effectively blocked MASH progression in preclinical models in both rodents and nonhuman primates. Collectively, the present study provides proof of concept that interference with GPR31 constitutes an attractive therapeutic strategy for MASH.


  • Open Access

    C118P Suppresses Gastric Cancer Growth via Promoting Autophagy–Lysosomal Degradation of RAB1A

    by Shihui Wei, Jing Zhang, Hai Wu, Zhengguang Liao, Zhengrui Liu, Yuhang Hou, Danyu Du, Jingwei Jiang, Li Sun, Shengtao Yuan, et al.

    Background/Objectives: Gastric cancer (GC) is the leading cause of cancer-related deaths worldwide. C118P, a microtubule inhibitor with anti-angiogenic and vascular-disrupting activities, was proven to be cytotoxic to various cancer cell lines. This study aimed to explore the anti-tumor effect of C118P against gastric cancer and identify its potential target. Methods: The MTT assay, colony formation assay, and EdU incorporation assay were used to evaluate the effect of C118P on GC cell proliferation. Cell cycle and cell apoptosis were measured using flow cytometry. Molecular docking, a microscale thermophoresis (MST) analysis, and the cellular thermal shift assay (CETSA) were used to investigate the binding of C118P to RAB1A. Autophagy-related effects were evaluated by using the MDC staining assay, immunofluorescence assay, and immunoblotting assay. The SGC-7901 cell line xenograft mouse model was used to confirm the anti-tumor efficacy of C118P. Results: C118P dramatically inhibited proliferation, induced G2/M cell cycle arrest, and triggered apoptosis in GC cell lines HGC-27 and SGC-7901. Mechanistically, C118P was demonstrated to bind with RAB1A and reduce the RAB1A protein level, accompanied by the inhibition of mTORC1 signaling. Moreover, C118P induced autophagosome formation and promoted RAB1A protein degradation in an autophagy–lysosomal-dependent manner. The in vivo study verified that C118P inhibits GC growth by inhibiting the RAB1A-mTOR axis. Conclusions: Our findings suggested that C118P inhibits GC growth by promoting the autophagy–lysosomal-dependent degradation of RAB1A and modulating mTOR C1 signaling. C118P shows potential as being a small molecule drug effective in the treatment of gastric cancer via targeting RAB1A.

  • Open Access

    Rolapitant treats lung cancer by targeting deubiquitinase OTUD3

    by Tongde Du, Quan Gu, Yonghui Zhang, Yujie Gan, Rongrui Liang, Wenzhu Yang, Ya Lu, Chenxin Xu, Jianzhong Wu, Rong Ma, et al.

    Background: Lung cancer is cancer with the highest morbidity and mortality in the world and poses a serious threat to human health. Therefore, discovering new treatments is urgently needed to improve lung cancer prognosis. Small molecule inhibitors targeting the ubiquitin-proteasome system have achieved great success, in which deubiquitinase inhibitors have broad clinical applications. The deubiquitylase OTUD3 was reported to promote lung tumorigenesis by stabilizing oncoprotein GRP78, implying that inhibition of OTUD3 may be a therapeutic strategy for lung cancer. Results: In this study, we identified a small molecule inhibitor of OTUD3, Rolapitant, by computer-aided virtual screening and biological experimental verification from FDA-approved drugs library. Rolapitant inhibited the proliferation of lung cancer cells by inhibiting deubiquitinating activity of OTUD3. Quantitative proteomic profiling indicated that Rolapitant significantly upregulated the expression of death receptor 5 (DR5). Rolapitant also promoted lung cancer cell apoptosis through upregulating cell surface expression of DR5 and enhanced TRAIL-induced apoptosis. Mechanistically, Rolapitant directly targeted the OTUD3-GRP78 axis to trigger endoplasmic reticulum (ER) stress-C/EBP homologous protein (CHOP)-DR5 signaling, sensitizing lung cancer cells to TRAIL-induced apoptosis. In the vivo assays, Rolapitant suppressed the growth of lung cancer xenografts in immunocompromised mice at suitable dosages without apparent toxicity. Conclusion: In summary, the present study identifies Rolapitant as a novel inhibitor of deubiquitinase OTUD3 and establishes that the OTUD3-GRP78 axis is a potential therapeutic target for lung cancer.


  • Multispecies transcriptomics identifies SIKE as a MAPK repressor that prevents NASH progression

    by Lan Bai, Weiyi Qu, Xu Cheng, Hailong Yang, Yong-Ping Huang, Zhenya Wang, Cuijuan Han, Rui-Feng Tian, Fengjiao Hu, Ling Yang, et al.

    Nonalcoholic fatty liver (NAFL) remains relatively benign, but high-risk to end-stage liver diseases become highly prevalent when it progresses into nonalcoholic steatohepatitis (NASH). Our current understanding of the development of NAFL to NASH remains insufficient. In this study, we revealed MAP kinase (MAPK) activation as the most notable molecular signature associated with NASH progression across multiple species. Furthermore, we identified suppressor of IKKε ( SIKE ) as a conserved and potent negative controller of MAPK activation. Hepatocyte-specific overexpression of Sike prevented NASH progression in diet- and toxin-induced mouse NASH models. Mechanistically, SIKE directly interacted with TGF-β–activated kinase 1 (TAK1) and TAK1-binding protein 2 (TAB2) to interrupt their binding and subsequent TAK1-MAPK signaling activation. We found that indobufen markedly up-regulated SIKE expression and effectively improved NASH features in mice and macaques. These findings identify SIKE as a MAPK suppressor that prevents NASH progression and provide proof-of-concept evidence for targeting the SIKE-TAK1 axis as a potential NASH therapy.


  • Open Access

    A Novel ASCT2 Inhibitor, C118P, Blocks Glutamine Transport and Exhibits Antitumour Efficacy in Breast Cancer

    by Xiao-Dan Lyu, Yang Liu, Jia Wang, Yuan-Cheng Wei, Yi Han, Xue Li, Qian Zhang, Zheng-Rui Liu, Zheng-Zheng Li, Jing-Wei Jiang, et al.

    Background: The microtubule protein inhibitor C118P shows excellent anti-breast cancer effects. However, the potential targets and mechanisms of C118P in breast cancer remain unknown. Methods: Real-time cellular analysis (RTCA) was used to detect cell viability. Apoptosis and the cell cycle were detected by flow cytometry. Computer docking simulations, surface plasmon resonance (SPR) technology, and microscale thermophoresis (MST) were conducted to study the interaction between C118P and alanine-serine-cysteine transporter 2 (ASCT2). Seahorse XF technology was used to measure the basal oxygen consumption rate (OCR). The effect of C118P in the adipose microenvironment was explored using a co-culture model of adipocytes and breast cancer cells and mouse cytokine chip. Results: C118P inhibited proliferation, potentiated apoptosis, and induced G2/M cell cycle arrest in breast cancer cells. Notably, ASCT2 was validated as a C118P target through reverse docking, SPR, and MST. C118P suppressed glutamine metabolism and mediated autophagy via ASCT2. Similar results were obtained in the adipocyte–breast cancer microenvironment. Adipose-derived interleukin-6 (IL-6) promoted the proliferation of breast cancer cells by enhancing glutamine metabolism via ASCT2. C118P inhibited the upregulation of ASCT2 by inhibiting the effect of IL-6 in co-cultures. Conclusion: C118P exerts an antitumour effect against breast cancer via the glutamine transporter ASCT2.


  • Open Access

    Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models

    by Yumeng Wang, Shujie Zhang, Huiqin He, Hongyi Luo, Yannan Xia, Yuanyuan Jiang, Jingwei Jiang, Li Sun

    Palmitoylation of proteins plays important roles in various physiological processes, such as cell proliferation, inflammation, cell differentiation etc. However, inhibition of protein palmitoylation has led to few new drugs to date. ZDHHC5 serves as a key enzyme to catalyze palmitoylation on SSTR5 (a proven anti-proliferation receptor in pancreatic cells). Herein, we compare single-cell transcriptome data between pancreatic cancer tissues and normal pancreas tissues and identify that ZDHHC5 is a potential target to inhibit proliferation of pancreatic cancer cells. In addition, we report the repositioning of an orphan drug (Lomitapide) as an inhibitor of ZDHHC5, and we speculate that this inhibitor may be able to block palmitylation on SSTR5. Pharmacological blockade of ZDHHC5 with Lomitapide results in attenuated cancer cell growth and proliferation which collectively contributes to antitumor responses in vitro and in vivo. This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of ZDHHC5 in pancreatic cancer, representing a new class of palmitoylation targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell palmitoylation.


  • Open Access

    C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma

    by Mei Yang, Yanhong Su, Zhiqiang Wang, Danyu Du, Shihui Wei, Zhengguang Liao, Qian Zhang, Liwen Zhao, Xian Zhang, Luwei Han, et al.